AM-2201
IUPAC | |
---|---|
| |
| |
CAS | 335161-24-5 |
PubChem | CID: 53393997 |
ChemSpider | 24751884 |
UNII | TBJ0966F1O |
KEGG | C22771 |
C24H22FNO | |
359.44 g/mol | |
| |
AM-2201、または1-(5-フルオロペンチル)-3-(1-ナフトイル)インドールは、カンナビノイド
有害 性
[薬理
[AM-2201は、カンナビノイド
薬物 動態
[AM-2201の
法律
[2015
関連 項目
[出典
[- ^ Wilkinson, S. M.; Banister, S. D.; Kassiou, M. (2015). “Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids”. Australian Journal of Chemistry 68 (1): 4–8. doi:10.1071/CH14198 .
- ^ David McQuade; Simon Hudson; Paul I. Dargan; David M. Wood (March 2013). “First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201”. European Journal of Clinical Pharmacology 69 (3): 373–376. doi:10.1007/s00228-012-1379-2. PMID 22936123 .
- ^ ekaJ (20 February 2011). “The Night I Killed My Friends”. Erowid.org. 11 June 2012
閲覧 。 - ^ Synthetic Drug Control Act of 2011. H.R. 1254, 112th Congress, 1st Session (2011).
- ^ Acute Kidney Injury Associated with Synthetic Cannabinoid Use, Multiple States, 2012. CDC morbitidy and mortality weekly report 2012.
- ^ Forbes Synthetic Marijuana May Cause Psychosis, Brain and Kidney Damage. Forbes report, Synthetic Marijuana Linked to Psychosis, Brain, and Kidney Damage. 2013
- ^ Dante Durand; Leticia L. Delgado; Dhizarah Matus de la Parra-Pellot; Diana Nichols-Vinueza (January 2015). “Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use”. Clinical Schizophrenia & Related Psychoses 8 (4): 205-208. doi:10.3371/CSRP.DUDE.031513. PMID 23518784 .
- ^ Bowling Green Daily News Report 2011. Bowling Green Daily News Report, 2011
- ^ Phys.org Report 2013. Phys.org Website, 2013
- ^ WO patent 0128557, Makriyannis A, Deng H, "Cannabimimetic indole derivatives", granted 2001-06-07
- ^ a b Banister, S. D.; Stuart, J.; Kevin, R. C.; Edington, A.; Longworth, M.; Wilkinson, S. M.; Beinat, C.; Buchanan, A. S. et al. (August 2015). “Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135”. ACS Chemical Neuroscience 6 (8): 1445–1458. doi:10.1021/acschemneuro.5b00107. PMID 25921407 .
- ^
世界 保健 機関 薬物 専門 委員 会 (2015年 11月). Follow up on recommendations made by 36th ECDD - Agenda item 4 (pdf) (Report). Expert Committee on Drug Dependence. 2017年 4月 12日 閲覧 。